慢性乙型肝炎合并代谢功能障碍或MASLD患者肝细胞癌及肝脏相关事件的预测
多中心纳入1922例合并至少一种代谢合并症的慢性乙型肝炎患者,MASLD占38.1%。肝硬化、年龄较大、血小板较低和白蛋白较低是HCC的独立危险因素。PAGE-B评分可对该人群进行HCC风险分层,无肝硬化且低评分者5年HCC发生率极低,但肝硬化患者即使低评分风险仍显著。
要点
- 合并代谢功能障碍或MASLD的CHB患者HCC风险显著,需重视风险分层。
- PAGE-B评分可有效分层HCC风险,低/中/高评分5年HCC风险分别为0.1%/2.0%/12.4%。
- 肝硬化患者即使PAGE-B低评分,5年HCC风险仍达4.2%,需谨慎管理。
核心结论
- 合并代谢功能障碍和/或MASLD的CHB患者HCC风险显著。
- PAGE-B评分可用于该人群HCC风险分层,无肝硬化且低评分者5年HCC发生率极低。
- 肝硬化患者即使PAGE-B低评分,HCC风险仍显著,应谨慎对待。
研究设计与样本
- 多中心回顾性队列研究,纳入9个中心1922例合并至少一种代谢合并症的CHB患者。
- 脂肪变通过超声、CAP或组织学诊断。
- 采用Cox回归分析HCC危险因素,并在总体人群及相关亚组中评估PAGE-B评分的性能。
主要发现
- 总体人群5年HCC风险在PAGE-B低/中/高评分组分别为0.1%/2.0%/12.4%(p < 0.001)。
- MASLD患者5年HCC风险在PAGE-B低/中/高评分组分别为0/2.8/11.1%(p < 0.001)。
- 无肝硬化患者中,PAGE-B低评分5年HCC风险为0%,中/高评分分别为1.2%和1.8%(p < 0.001)。
- 肝硬化患者中,PAGE-B低/中/高评分5年HCC风险分别为4.2%/6.9%/27.3%(p < 0.001)。
- 肝硬化、年龄较大、血小板较低和白蛋白较低是HCC的独立危险因素。
关键数值与推荐
- PAGE-B低/中/高评分对应总体人群5年HCC风险0.1%/2.0%/12.4%。
- MASLD患者PAGE-B低/中/高评分对应5年HCC风险0/2.8/11.1%。
- 无肝硬化患者PAGE-B低/中/高评分对应5年HCC风险0%/1.2%/1.8%。
- 肝硬化患者PAGE-B低/中/高评分对应5年HCC风险4.2%/6.9%/27.3%。
临床怎么用
- 对合并代谢功能障碍或MASLD的CHB患者应进行HCC风险分层管理。
- PAGE-B评分可用于识别无肝硬化且低评分的极低HCC风险患者。
- 肝硬化患者即使PAGE-B低评分也应保持HCC监测,因风险仍显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Metabolic dysfunction and metabolic dysfunction-associated steatotic liver disease (MASLD) are associated with an increased risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). We aimed to study risk factors for HCC and to assess the performance of the PAGE-B score in this population. METHODS: We included CHB patients with ≥ 1 metabolic comorbidity from nine centres. Steatosis was diagnosed by ultrasound, CAP, or histology. Risk factors were analysed by Cox regression, and the performance of the PAGE-B score was assessed in the overall population and across relevant subgroups. RESULTS: We included 1922 patients. 1730 (90.0%) were overweight, 434 (22.6%) had hypertension, 254 (13.2%) dyslipidemia, 230 (12.0%) diabetes and 732 (38.1%) MASLD. Presence of cirrhosis, older age, lower platelets and lower albumin were independent risk factors for HCC. The 5-year HCC risk was 0.1%/2.0%/12.4% patients with low/intermediate/high PAGE-B scores (p < 0.001). Consistent results were obtained in patients with MASLD (0/2.8/11.1% for low, intermediate and high PAGE-B scores (p < 0.001)). PAGE-B stratified risk in patients without cirrhosis (0% vs. 1.2% and 1.8%, p < 0.001). Among the subset of patients with cirrhosis, risks were 4.2% (low), 6.9% (intermediate) and 27.3% (high) (p < 0.001). CONCLUSIONS: CHB patients with metabolic dysfunction and/or MASLD are at significant risk of HCC. The PAGE-B score can be used to stratify HCC risk in this population, with negligible 5-year HCC incidence in those without cirrhosis and low PAGE-B scores. However, caution should be exercised in patients with cirrhosis in whom HCC risk remains significant even among those with a low PAGE-B score.
引用
- Patmore LA, Carey I, Feld JJ, et al. Prediction of Hepatocellular Carcinoma and Other Liver-Related Events in Chronic Hepatitis B Patients With Metabolic Dysfunction or Metabolic Dysfunction-Associated Steatotic Liver Disease. Aliment Pharmacol Ther. 2025. PMID: 40922677. doi:10.1111/apt.70360
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。